FLINT, Mich., Oct. 22, 2015 /PRNewswire/
-- Diplomat Pharmacy, Inc. (NYSE: DPLO)
announced that it has secured the ability to dispense Coagadex
(coagulation factor X, human) to its patients from Bio Products
Laboratory Limited (BPL), a leading manufacturer of plasma-derived
protein therapies. Coagadex was approved by the U.S. Food and Drug
Administration (FDA) on Oct. 20,
2015. Coagadex is the first and only FDA-approved product to
treat hereditary factor X deficiency, and is the only factor X
concentrate available in the U.S.
Factor X ("ten") deficiency is a rare, inherited bleeding
disorder caused by inadequate levels of clotting factor X protein
in the blood. Similar to hemophilia A and hemophilia B, factor X
deficiency is characterized by episodes of prolonged spontaneous
bleeding. As one of the rarest bleeding disorders, it affects
approximately 300 to 600 patients in the U.S. The goal of treatment
in patients with hereditary factor X deficiency is to replace their
missing factor X without adding other clotting factors the patients
do not need.
"We are pleased to be selected as a provider of Coagadex," said
Phil Hagerman, chairman and CEO of
Diplomat. "Diplomat and its specialty infusion companies, AHF,
BioRx and MedPro Rx, are strong supporters of the bleeding
disorders community. We are excited to work with BPL to deliver a
highly specialized home treatment option for patients with this
rare bleeding disorder."
In an effort to promote a high level of service to this patient
community, BPL will provide specialized disease state and Coagadex
product training to Diplomat employees.
Diplomat and its affiliate companies expect to begin
distribution of Coagadex in December
2015.
Please see the full prescribing information for Coagadex at
www.coagadex.com.
To learn more about Diplomat, visit www.diplomat.is.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended December 31,
2014 and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) serves patients and physicians in all 50
states. Headquartered in Flint,
Michigan, the company focuses on medication management
programs for people with complex chronic diseases, including
oncology, immunology, hepatitis, multiple sclerosis, HIV,
specialized infusion therapy and many other serious or long-term
conditions. Diplomat opened its doors in 1975 as a neighborhood
pharmacy with one essential tenet: "Take good care of patients, and
the rest falls into place." Today, that tradition continues—always
focused on improving patient care and clinical adherence. For more
information visit www.diplomat.is. Follow us on Twitter and
LinkedIn and like us on Facebook.
CONTACT:
Kali
Lucas, Public Relations Coordinator
810.768.9580 | press@diplomat.is
Gary Rice, RPh, MS, MBA, CSP,
Vice President, Clinical Services
810.768.9863 | grice@diplomat.is
Logo - http://photos.prnewswire.com/prnh/20140928/148820
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/diplomat-to-distribute-coagadex-for-the-treatment-of-hereditary-factor-x-deficiency-300164496.html
SOURCE Diplomat Pharmacy, Inc.